Amgen (AMGN) : Centurylink Investment Management Co scooped up 413 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 12, 2016. The investment management firm now holds a total of 19,499 shares of Amgen which is valued at $3,204,076.Amgen makes up approximately 1.10% of Centurylink Investment Management Co’s portfolio.
Other Hedge Funds, Including , Osborn Rohs Williams Donohoe Ltd reduced its stake in AMGN by selling 1,515 shares or 6.54% in the most recent quarter. The Hedge Fund company now holds 21,638 shares of AMGN which is valued at $3,555,556. Amgen makes up approx 0.69% of Osborn Rohs Williams Donohoe Ltd’s portfolio.Oliver Luxxe Assets boosted its stake in AMGN in the latest quarter, The investment management firm added 467 additional shares and now holds a total of 3,849 shares of Amgen which is valued at $644,708. Amgen makes up approx 0.51% of Oliver Luxxe Assets’s portfolio.Indiana Trust Investment Management Co reduced its stake in AMGN by selling 45 shares or 2.01% in the most recent quarter. The Hedge Fund company now holds 2,189 shares of AMGN which is valued at $366,088. Amgen makes up approx 0.19% of Indiana Trust Investment Management Co’s portfolio. Curbstone Financial Management Corp added AMGN to its portfolio by purchasing 2,410 company shares during the most recent quarter which is valued at $403,048. Amgen makes up approx 0.13% of Curbstone Financial Management Corp’s portfolio.Burns J W Co Incny boosted its stake in AMGN in the latest quarter, The investment management firm added 4,708 additional shares and now holds a total of 9,978 shares of Amgen which is valued at $1,668,721. Amgen makes up approx 0.52% of Burns J W Co Incny’s portfolio.
Amgen closed down -3.99 points or -2.37% at $164.32 with 27,61,896 shares getting traded on Tuesday. Post opening the session at $167.82, the shares hit an intraday low of $163.51 and an intraday high of $167.82 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.